August 28, 2020 Ms. Shalini Sharp Executive Vice President and Chief Financial Officer Ultragenyx Pharmaceutical Inc. Novato, CA 94949 Re: Amendment No. 1 to Transition Letter Agreement Dear Shalini: On behalf of Ultragenyx Pharmaceutical Inc. (the...Transition Letter Agreement • September 2nd, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This Confidential Transition Agreement and General Release (this “Agreement”) is hereby entered into by and between Shalini Sharp, an individual (the “Employee”), and Ultragenyx Pharmaceutical Inc., on behalf of itself and all of its affiliated entities (collectively, the “Company”).
